Identification of PRDX5 as A Target for The Treatment of Castration-Resistant Prostate Cancer

By sjmartinez • December 20, 2023

Wang R, Mi Y, Ni J, Wang Y, Ding L, Ran X, Sun Q, Tan SY, Koeffler HP, Feng N, Chen YQ. Identification of PRDX5 as A Target for The Treatment of Castration-Resistant Prostate Cancer. Adv Sci (Weinh). 2023 Dec 20:e2304939. doi: 10.1002/advs.202304939. Epub ahead of print. PMID: 38115765.

Tags: castration-resistant prostate cancer, Cedars Sinai DoM, Drug-tolerant persister, Hematology/Oncology, peroxiredoxin 5, polaprezinc, Publications, stachyose

AI-CVD-AF: A Novel Atrial Fibrillation Prediction Model Based on Coronary Artery Calcium Scans

Mirjalili SR, Atlas K, Reeves AP, Zhang C, Wasserthal J, Azimi A, Hashemi A, Mozafarybazargany M, Atlas T, Henschke CI, Yankelevitz DF, Zulueta JJ, Fan[...]

Are Urologists and/or Radiation Oncologists Biased when Reporting of Advantages and Disadvantages of Surgery versus Radiation in Consultations for Early-Stage Prostate Cancer?

Friedrich NA, Luu M, Gale R, Chaplin A, Polineni R, Shiang A, Shin D, Freedland SJ, Spiegel B, Ballas LK, Kokorowski P, Daskivich TJ. Are[...]

Charting the translational pathway: ISSCR best practices for the development of PSC-derived therapies

Barry J, Abranches E, Baptista RP, Barry C, Brandsten C, Bruce K, Carpenter MK, Cavagnaro J, Collins L, Csaszar E, Dashnau J, de Villa D,[...]